Resistance to current human epidermal growth factor receptor 2 (HER2) inhibitors, such as trastuzumab (Ttzm), is a major unresolved clinical problem in HER2-positive breast cancer (HER2-BC). Because HER2 remains overexpressed in drug-resistant HER2-BC cells, we investigated whether PEPD G278D can overcome the resistance. PEPD G278D is a recombinant enzymatically inactive mutant of human peptidase D, which strongly inhibits HER2 in cancer cells by binding to its extracellular domain. Here, we show that PEPD G278D is highly active in preclinical models of HER2-BC resistant to Ttzm and other HER2 inhibitors and also enhances the therapeutic efficacy of paclitaxel. The therapeutic activity is underscored by its ability to bind to HER2 and free it from protection by mucin 4, disrupt its interplay with other receptor tyrosine kinases, and subsequently direct HER2 for degradation. PEPD G278D also down-regulates epidermal growth factor receptor, which contributes to drug resistance in HER2-BC. In contrast, Ttzm, whose therapeutic activity also depends on its binding to the extracellular domain of HER2, cannot perform any of these functions of PEPD
INTRODUCTION
HER2 is an oncogenic receptor tyrosine kinase (RTK) implicated in several types of human cancer. It is strongly expressed in about 20% of breast cancer (BC), known as HER2-positive BC (HER2-BC), due to gene amplification (1, 2) . HER2 amplification or overexpression is a strong predictor of poor disease prognosis (3, 4) . HER2-targeting drugs are available for treating HER2-BC, including monoclonal antibodies Ttzm and pertuzumab, T-DM1 (Ttzm coupled to a microtubule inhibitor), and tyrosine kinase inhibitors (TKIs) lapatinib and neratinib. Although these agents have greatly improved disease outcomes, primary and acquired drug resistance is common. Ttzm, the mainstay treatment for HER2-BC, achieves an overall response rate of about 25% as a single agent and about 50% when combined with chemotherapy in metastatic disease (5, 6) . Most patients with advanced disease show disease progression after some time on treatment. Even the triple combination of Ttzm, pertuzumab, and docetaxel produces median progression-free survival of only about 18 months (7). Many drug resistance mechanisms have been reported, including decreased drug binding to HER2 (8, 9) , activation of compensatory signaling (10, 11) , defects in apoptosis and cell cycle control (12, 13) , and host factors (14, 15) . However, the relative importance of these mechanisms is poorly understood, hampering the development of better therapies.
One of the mechanisms of action of Ttzm is HER2 down-regulation, but Ttzm is relatively weak or inactive in down-regulating HER2 in tumors in vivo (11, 16, 17) , which may be an important reason for its therapeutic limitation. We recently found that recombinant human peptidase D (PEPD), also known as prolidase, strongly downregulates HER2 and epidermal growth factor receptor (EGFR) in cancer cells in vitro and in vivo. Whereas endogenous PEPD residing intracellularly has no effect on HER2 and EGFR, exogenously administered PEPD binds to the extracellular domains (ECDs) of the receptors, disrupting their signaling and down-regulating their expression in cancer cells overexpressing the receptors, resulting in growth inhibition (18, 19) . However, PEPD does not bind to other HER family members, including HER3 and HER4 (20) . The enzymatic activity of PEPD plays no role in its modulation of HER2 and EGFR, and we subsequently focused on recombinant PEPD G278D , an enzymatically inactive mutant (point mutation at codon 278). PEPD G278D specifically binds to HER2 and EGFR, and cells and tumors lacking these receptors are insensitive to it (18, 19) . Its ability to target both HER2 and EGFR is important because EGFR is expressed in 35 to 40% of HER2-BC, and its expression is associated with worse survival (21, 22) . PEPD G278D differs from the clinically available TKIs of HER2 and EGFR because the TKIs target the kinase domains of the receptors. Here, we investigated the therapeutic activity and mechanism of action of PEPD G278D in cell lines and mouse models of HER2-BC resistant to Ttzm and other HER2 inhibitors. G278D and Ttzm on cell proliferation, measured by MTT assay. Each value is mean ± SD (n = 3). ****P < 0.0001 by one-way analysis of variance (ANOVA), followed by Tukey test for comparison to the control. (C) IB analysis of whole-cell lysates from cells treated with vehicle, PEPD G278D (25 nM), or Ttzm (1 M) for 48 hours. The following phosphorylation sites were measured: pY1221/1222-HER2, pY1173-EGFR, pY416-SRC, pS473-AKT, pT202/Y204-ERK, pY1131-IGF1R, and pY1234/1235-MET. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was measured as a loading control here and elsewhere.
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Fig. 1. PEPD G278D targets HER2-BC cells resistant to Ttzm. (A) Immunoblotting (IB) analysis of whole-cell lysates from untreated cells. (B) Effects of PEPD
to both pertuzumab and lapatinib (26, 27 (29) . Despite PIK3CA mutations, PTEN loss, cyclin E overexpression, and difference in BC subtype, PEPD G278D caused concentration-and time-dependent growth inhibition in all the HER2-BC cell lines, whereas Ttzm was active only in BT-474, even at 40-fold higher concentration than PEPD G278D (Fig. 1B) . PEPD G278D was moderately active in HCC-1569 cells, which show relatively low expression of HER2 and EGFR, and was inactive in MCF-7 cells, which lack both receptors; the result is consistent with PEPD G278D being a specific dual inhibitor of HER2 and EGFR. Upon PEPD G278D treatment (25 nM, 48 hours), all the cell lines except MCF-7 showed profound loss of HER2 and EGFR (both expression and phosphorylation), loss of phosphorylation (inactivation) of all key downstream signaling partners analyzed, including SRC, AKT, and ERK (extracellular signal-regulated kinase), and loss of phosphorylation of RTKs which heterodimerize with HER2, including IGF1R (insulin-like growth factor 1 receptor) and MET (c-MET) (Fig. 1C) . SRC, AKT, ERK, IGF1R, and MET all play important roles in HER2-BC resistance to current HER2 inhibitors (10, 11, 30, 31) . PEPD G278D -induced changes in SRC, AKT, ERK, IGF1R, and MET apparently resulted from the inhibition of HER2 and EGFR because none of the changes occurred in MCF-7 cells (Fig. 1C) . Ttzm (1 M, 48 hours) had moderate effects on HER2, SRC, AKT, and ERK but no effect on EGFR, IGF1R, and MET in BT-474 and no effect on any of these proteins in any of the other cell lines (Fig. 1C) .
Our results show that PEPD G278D is effective against HER2-BC cells resistant to Ttzm and other HER2 inhibitors. These results also show that HER2-BC cells that are resistant to current HER2 inhibitors still require HER2 for survival and growth. HER2 knockdown by small interfering RNA (siRNA) also inhibits HER2-BC cells resistant to Ttzm and lapatinib (32, 33) . PEPD G278D also targets EGFR, which likely contributes to its activity, because EGFR knockdown by siRNA decreased the survival of both BT-474R2 and JIMT-1 cells (fig. S1, J and K). Neratinib, a pan-HER TKI, was also active in JIMT-1 and BT-474R2 cells but appeared less potent than PEPD G278D ( fig. S1L ).
PEPD G278D induces internalization and lysosomal degradation of HER2 in drug-resistant HER2-BC cells
Because both PEPD G278D and Ttzm bind to HER2 ECD, at subdomain 3 for PEPD G278D (20) and subdomain 4 for Ttzm (34), we sought to address how PEPD G278D succeeded in inhibiting HER2 in cells that failed Ttzm. In both BT-474R2 and JIMT-1 cells, HER2 began to decrease after 2 to 3 hours of PEPD G278D treatment (25 nM) , decreased markedly at 6 hours and was almost undetectable at 24 hours, accompanied by initial increase in p-HER2 ( Fig. 2A) , which is consistent with PEPD G278D -induced HER2 dimerization, followed by internalization and degradation. In contrast, Ttzm was totally inactive even at 1 M (Fig. 2B) . PEPD G278D did not modulate HER2 gene transcription (Fig. 2C) . Because RTK amounts are regulated by internalization and lysosomal degradation, we asked whether lysosome inhibition would rescue HER2 in PEPD G278D -treated cells. Chloroquine, a lysosome inhibitor, had no effect on baseline HER2 expression but completely blocked PEPD G278D -induced HER2 loss (Fig. 2D ) and caused accumulation of internalized HER2 (Fig. 2E) . PEPD G278D appeared to bind to HER2 on cell surface before cointernalization (Fig. 2F) . Chloroquine-induced accumulation of internalized HER2 colocalized with lysosomal-associated membrane protein 1 (LAMP1) (Fig. 2G) .
Because PEPD G278D is internalized with HER2, we investigated whether PEPD G278D can also modulate nuclear HER2 and EGFR, which are implicated in cancer cell growth and drug resistance (35, 36) . However, treatment of BT-474R2 or JIMT-1 cells with PEPD G278D up to 250 nM had no effect on nuclear expression of HER2 and EGFR ( fig. S2A ). Endogenous PEPD was recently found to bind and regulate p53 (37) . However, PEPD G278D showed no effect on p53, with no disruption of the endogenous PEPD-p53 complex, no binding of PEPD G278D to p53, and no change in p53 transcriptional activity ( fig. S2 , B to E). Thus, internalized PEPD G278D does not appear to be biologically active.
PEPD G278D binds and frees HER2 from MUC4 Membrane-associated mucin 4 (MUC4) binds and stabilizes HER2 (38, 39) and prevents Ttzm from binding to HER2 (8, 38) . We found that all Ttzm-resistant HER2-BC cell lines in this study strongly overexpress MUC4 (Fig. 3A) . In BT-474R2 cells, about 10 times more PEPD G278D than Ttzm bound to HER2, although the PEPD G278D concentration was 40-fold lower than that of Ttzm ( fig. S3A ). Pertuzumab bound to HER2 about 4 times better than Ttzm in BT-474R2 cells, showed a negligible effect on cell proliferation, but antagonized PEPD G278D in both HER2 binding and inhibition of cell proliferation ( fig. S3 , B and C). Pertuzumab antagonism toward PEPD G278D is expected, however, because it binds to subdomain 2 of HER2 ECD to block HER2 dimerization (40) , whereas PEPD G278D functions by causing HER2 dimerization. In both JIMT-1 and BT-474R2 cells, MUC4 knockdown by siRNA markedly decreased the amount of HER2 and cell survival (Fig. 3 , B and C). Conversely, both BT-474 and SKBR3 cells (HER2-positive BC cells) are MUC4 low and Ttzm sensitive, and overexpressing MUC4 markedly reduced their sensitivity to Ttzm but not to PEPD G278D (Fig. 3, D and E). MUC4 overexpression did not completely protect the cells from Ttzm, probably because gene transfection efficiency is unlikely to be 100%. In both BT-474R2 and JIMT-1 cells, PEPD G278D binds to HER2 and frees it from MUC4 ( Fig. 3F) , without altering MUC4 expression ( fig. S3D ). Thus, although MUC4 overexpression may play a crucial role in resistance to Ttzm and other HER2 inhibitors in HER2-BC cells, it has no effect on HER2 targeting by PEPD
G278D
. In both BT-474R2 and JIMT-1 cells, PEPD G278D (homodimer) underwent two phases of HER2 binding: rapid binding to preexisting HER2 homodimer (no change in HER2 monomer content, decrease in HER2 dimer content, and formation of heterotetramer of one HER2 dimer and one PEPD G278D dimer at 10 min), followed by binding to HER2 monomer, leading to decrease in HER2 monomer content, formation of heterotrimer (one HER2 monomer and one PEPD G278D dimer), and further increase in heterotetramer content at 60 min (Fig. 3G ). The heterotrimer is presumably an intermediate. New HER2 dimers were detected after PEPD G278D treatment, which likely resulted from dissociation of some heterotetramers during sample preparation. In contrast, each molecule of Ttzm binds to a HER2 monomer (34) .
PEPD
G278D disrupts HER2 heterodimers Phosphorylation of IGF1R and MET was abolished in all the HER2-BC cell lines treated with PEPD G278D , whereas Ttzm was inactive (Fig. 1C) . Both IGF1R and MET contribute to Ttzm resistance in HER2-BC (10, 31).
Because HER2 forms heterodimeric signaling units, and PEPD G278D disrupts HER2-EGFR and HER2-HER3 heterodimers (18) but showed no effect on phosphorylation and expression of vascular endothelial growth factor receptor-1 (VEGFR-1), which is not known to dimerize with HER2 ( fig. S4A ), we asked whether PEPD G278D disrupts HER2 heterodimerization with IGF1R and MET. Chinese hamster ovary (CHO)-K1 cells express very low amounts of HER2 and none of its family members (20) . We overexpressed human HER2 in these cells (CHO-K1/HER2). Neither IGF1R nor MET was affected by PEPD G278D in CHO-K1 cells, whereas phosphorylation of both proteins, but not their expression, was abolished in PEPD G278D -treated CHO-K1/HER2 cells, along with HER2 loss (Fig. 4A) . Moreover, whereas IGF1, a ligand of IGF1R, stimulated IGF1R phosphorylation in both CHO-K1 and CHO-K1/HER2 cells, PEPD G278D abolished IGF1R phosphorylation only in CHO-K1/HER2 cells ( fig. S4B) . Thus, the impact of PEPD G278D on MET and IGF1R appears to be mediated by HER2. Both BT-474R2 and JIMT-1 cells contained HER2-IGF1R and HER2-MET heterodimers, which were stimulated by IGF1 or MET ligand hepatocyte growth factor (HGF) (Fig. 4 , B and C). Treatment with PEPD G278D (25 nM) for only 1 hour caused profound disruption of both heterodimers, regardless of ligand involvement (Fig. 4 , B and C), whereas the expression of IGF1R and MET remained unchanged (fig. S4, C and D). PEPD G278D bound to HER2 but not to IGF1R or MET in both cell lines, and PEPD G278D appeared to disrupt HER2 association with IGF1R or MET even when the latter RTKs were bound by their ligands (Fig. 4 , D and E). HER2 phosphorylation increased upon PEPD G278D treatment (Fig. 4 , D and E), which is consistent with PEPD G278D -induced HER2 homodimerization before internalization and degradation (20) . The ability of PEPD G278D to simultaneously suppress multiple oncogenic RTKs directly or indirectly further shows its therapeutic potential.
G278D shows therapeutic activity in vivo PEPD G278D was compared with Ttzm in two orthotopic models of HER2-BC. PEPD G278D was evaluated in combination with enoxaparin (EP), a clinically used anticoagulant, because PEPD G278D is degraded by coagulation proteases in vivo, and EP blocks the degradation (18, 41) . EP does not interfere with modulation of EGFR and HER2 by PEPD G278D and does not affect tumor growth itself (18, 19) .
JIMT-1 cells, which show primary drug resistance, were inoculated into the mammary fat pads of female severe combined immunodeficient (SCID) mice. The mice were randomized and treated with EP, PEPD G278D plus EP, or Ttzm once tumors reached 100 to 150 mm 3 . EP was given by intraperitoneal injection at 0.5 mg/kg body weight daily to inhibit PEPD G278D degradation (19) . PEPD G278D was given intraperitoneally at 4 mg/kg thrice weekly, starting 5 days after EP to ensure that the mice were fully primed by EP (19) . Ttzm was given intraperitoneally at 10 mg/kg weekly (25) . EP is given to patients by subcutaneous injection, and PEPD
G278D
, if advanced to clinical testing, will likely be given intravenously, but similar plasma concentrations of PEPD G278D were obtained regardless of administration routes of the agents ( fig. S5 ). Whereas tumors in mice treated by EP alone grew rapidly and Ttzm had no effect on tumor growth, PEPD G278D caused rapid tumor regression, followed by complete remission of all the tumors, with no recurrence after 2 months of follow-up (Fig. 5A) . In contrast, a previous study showed that even combining Ttzm with pertuzumab (~5 mg/kg intraperitoneally twice weekly for each agent) and starting the treatment at the time of cell inoculation did not cause tumor regression in this model (27) , although pertuzumab has synergistic activity with Ttzm (42) . To obtain tumor samples for molecular analysis, we randomly divided mice in the EP group either to continue EP treatment only or to receive PEPD G278D on days 27 and 29 while continuing EP treatment; PEPD G278D addition caused rapid tumor regression again (Fig. 5A ). There was no sign of agent toxicity. In tumors obtained 24 hours after the last treatment, PEPD G278D caused almost total loss of HER2, p-HER2, EGFR, p-EGFR, p-HER3, p-IGF1R, p-MET, p-SRC, p-AKT, p-ERK, and strong activation of caspase 3, without altering the expression of HER3, neuregulin-1 (NRG-1; HER3 ligand), IGF1R, MET, Each value in (C) and (E) is mean ± SD (n = 3). **P < 0.01, ***P < 0.001, ****P < 0.0001 by paired two-tailed t test.
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SRC, AKT, or ERK, whereas Ttzm had no effect (Fig. 5B ). NRG-1, which may contribute to Ttzm resistance (43), was not overexpressed in JIMT-1 and BT-4742R2 cells ( fig. S6A ). PEPD G278D blocked NRG-1-induced phosphorylation of both HER3 and AKT, and its inhibition of cell proliferation was not attenuated by NRG-1 ( fig. S6 , B to D). PEPD G278D disrupts HER3 heterodimerization with HER2 (18). BT-474R2 cells, which show acquired drug resistance, grew poorly in SCID mice and were inoculated into the mammary fat pads of female athymic nude mice. The mice were randomized and treated with EP, PEPD G278D plus EP, or Ttzm, as described above. Ttzm was ineffective, whereas PEPD G278D rapidly arrested tumor growth (Fig. 5C ). However, PEPD G278D did not induce tumor regression but rather induced a senescence-like state because the treated tumors neither grew nor regressed, and the remnants were tumor tissues not fibrosis ( fig. S7A ). In BT-474R2 tumors obtained 24 hours after the last treatment, PEPD G278D caused the same molecular changes as in JIMT-1 tumors, whereas Ttzm was inactive (Fig. 5B) . Thus, the inability of PEPD G278D to induce tumor regression is not due to inadequate targeting of HER2 and its signaling partners. Increasing PEPD G278D dose to 8 mg/kg did not induce tumor regression (Fig. 6, A and B) . BT-474R2 cells overexpress cyclin E1, which confers resistance to Ttzm (13) . PEPD G278D showed no effect on cyclin E1 (Fig. 6C) . However, it is not clear whether cyclin E1 overexpression contributes to PEPD G278D 's inability to induce tumor regression. There was no sign of agent toxicity. Despite strong effect of PEPD G278D on HER2 and EGFR in the tumors, neither PEPD G278D nor Ttzm affected the expression of the RTKs in vital organs (heart, kidney, and liver), except a slight increase in HER2 phosphorylation in the heart by both agents (fig. S7B ). PEPD G278D also had no effect on the histology of these organs in mice in our previous study (18) . The expression levels of both EGFR and HER2 were very low in these organs, compared to that in the tumor tissues ( fig. S7C) , suggesting that PEPD G278D may primarily target the RTKs overexpressed in cancer cells.
Combination of PEPD
G278D with paclitaxel enhances therapeutic outcome Paclitaxel is commonly used to treat HER2-BC. However, HER2 inhibits paclitaxel-induced apoptosis in BC cells by inducing Y15 phosphorylation of CDC2 and p21 up-regulation (44, 45) . To assess the therapeutic benefit of PEPD G278D combination with paclitaxel, mice bearing BT-474R2 tumors were treated with EP, as described before, paclitaxel (20 mg/kg intraperitoneally weekly), PEPD G278D (8 mg/kg intraperitoneally thrice weekly) plus EP, or PEPD G278D (4 mg/kg intraperitoneally thrice weekly) plus EP and paclitaxel. Both paclitaxel and PEPD G278D inhibited tumor growth as single agents (Fig. 6A) , but the final tumor weights between EP and paclitaxel were not statistically different (Fig. 6B) . Whereas PEPD G278D did not induce tumor regression even at 8 mg/kg, combining PEPD G278D with paclitaxel resulted in tumor regression, and despite the short treatment time selected to obtain an adequate amount of tumor tissue for molecular analysis, 60% of the tumors already achieved complete remission. There was no detectable treatment toxicity. Paclitaxel, which targets microtubules, had no effect on any of the molecules measured in the tumors except for caspase 3 activation, but tumors treated by PEPD G278D with or without paclitaxel showed profound loss of HER2, p-HER2, EGFR, p-EGFR, p-HER3, p-IGF1R, p-MET, p-SRC, p-AKT, p-ERK, p-CDC2, and p21; whereas the expression of cyclin E1, HER3, NRG-1, IGF1R, MET, SRC, AKT, ERK, and CDC2 remained unchanged (Fig. 6C) . Caspase 3 activation was more pronounced in tumors treated by PEPD G278D plus paclitaxel than by a single agent (Fig. 6C) , which is consistent with their tumor inhibitory efficacies. PEPD G278D with or without paclitaxel also markedly decreased p-CDC2 and p21 in cultured BT-474R2 and JIMT-1 cells (Fig. 6D and fig. S8 ).
DISCUSSION
In this study, we demonstrate the therapeutic activity of PEPD G278D against HER2-BC resistant to current HER2 inhibitors. PEPD G278D exerts its action in two phases ( fig. S9 ). In phase 1, which is well underway at 1 hour of treatment, PEPD G278D frees HER2 from MUC4 and disrupts the interaction of HER2 with other RTKs, including MET and IGF1R. PEPD G278D also disrupts HER2 interaction with EGFR and HER3 (18) , whose heterodimerization with HER2 contributes to HER2-BC aggressiveness (21, 46) . PEPD G278D apparently disrupts HER2 heterodimerization by forcing its homodimerization. PEPD G278D also binds to preformed HER2 homodimers and disassembles their signaling unit, thereby causing SRC to dissociate from the dimer (20) . Thus, PEPD G278D rapidly suppresses multiple RTKs either directly or indirectly in HER2-BC cells. In phase 2, which begins at 2 to 3 hours of PEPD G278D treatment, PEPD G278D induces persistent down-regulation of HER2 via internalization and lysosomal degradation. In addition, PEPD G278D down-regulates EGFR, apparently by binding to the receptor to induce its internalization and degradation (18, 19) .
Our results also provide insight into the drug resistance mechanism in HER2-BC. All Ttzm-resistant HER2-BC cell lines tested were (C) BT-474R2 tumors in nude mice, treated with EP daily (days 1 to 34, n = 13), Ttzm weekly (days 6 to 34, n = 15), or EP daily (days 1 to 34) plus PEPD G278D thrice weekly (days 6 to 34, n = 12). All tumors were harvested 24 hours after the last treatment. EP, Ttzm, and PEPD G278D were dosed intraperitoneally at 0.5, 10, and 4 mg/kg per dose, respectively. Each value in (A) and (C) is mean ± SEM. **P < 0.01, ****P < 0.0001 by one-way ANOVA, followed by Tukey test; n.s., not significant.
exquisitely sensitive to PEPD G278D , despite carrying activating PIK3CA mutations, low expression of PTEN, and/or cyclin E overexpression. The therapeutic activity of PEPD G278D highlights that HER2 remains a critical target in drug-resistant HER2-BC. All Ttzm-resistant cell lines overexpressed MUC4, and overexpressing MUC4 in Ttzm-sensitive cells converted them to Ttzm resistance. In addition to shielding HER2 from Ttzm, MUC4 also stabilizes HER2 and therefore may confer resistance to other HER2 inhibitors. MUC4 overexpression may be the key factor responsible for drug resistance in HER2-BC, whereas increased signaling downstream of HER2 may confer resistance to therapy if HER2 is not strongly inhibited. For example, studies have shown that the gain of function induced by helical domain mutations of PI3KCA such as E545A requires interaction with RAS, and the gain of function induced by kinase domain mutations of PI3KCA such as H1047R is modulated by the regulatory subunit p85 and phosphorylated RTKs (47, 48) . In PEPD
G278D
-treated HER2-BC cells, phosphorylation of multiple RTKs was lost, and RAS was likely inhibited in view of loss of ERK phosphorylation, thereby limiting the impact of PI3KCA mutation. The reason why MUC4 shields HER2 from Ttzm but not PEPD G278D is unknown but may be related to how Ttzm and PEPD G278D bind to HER2. Each subunit of homodimeric PEPD G278D binds to a HER2 monomer, forming a tetracomplex, which may be relatively stable and may disrupt MUC4 binding to HER2 by steric hindrance or inducing conformation change of HER2. Each molecule of Ttzm binds to one HER2 monomer (34) . The finding that MUC4 has no effect on PEPD
targeting of HER2 is important because a recent study shows that MUC4 is positive in 60% of human HER2-BCs and is an independent predictor of poor diseasefree survival in patients treated with Ttzm (38) . Our finding that combining paclitaxel with PEPD G278D improves antitumor outcome offers a potential combination approach. In the present study, PEPD G278D was used in combination with EP for PEPD G278D to escape degradation in the plasma in vivo. It will be important to investigate whether PEPD G278D can be structurally modified to resist degradation without EP while retaining its antitumor activity. However, the EP dose for inhibition of PEPD G278D degradation is much lower than for anticoagulation (49, 50) . Moreover, because increased coagulation and thromboembolic disease affect a high percentage of patients with cancer (51, 52) , combination of PEPD G278D and EP may be beneficial.
There are limitations to this study. First, because PEPD G278D is a human protein, it could not be evaluated in tumor models in immunocompetent mice. Second, the tumor models used in our study did not show metastasis and therefore did not allow evaluation of potential effect of PEPD G278D on tumor metastasis. Nevertheless, given the strong therapeutic activity of PEPD G278D shown in the present study, it may also be effective against metastatic HER2-BC. JIMT-1 cells, which were derived from pleural effusion of a patient (25) , were exceedingly sensitive to PEPD G278D . Third, p95HER2, a truncated form of HER2 lacking its ECD, confers resistance to Ttzm (9) and would be insensitive to PEPD G278D , potentially limiting the effectiveness of PEPD G278D . Last, we did not have access to patient-derived xenograft (PDX) models of drug-resistant HER2-BC. Because PDX models are recognized to conserve the heterogeneity typical of the original patient tumors and to reliably predict disease response to therapies, evaluation of PEPD G278D in such a model, once becoming available, would be worthwhile.
Additional preclinical evaluation of both therapeutic efficacy and safety of PEPD G278D produced in compliance with Good Manufacturing Practice regulations will be needed before PEPD G278D can be investigated clinically. Particularly, given the cardiotoxicity of current HER2 inhibitors, evaluation of potential effects of PEPD G278D on cardiac function is needed. However, our present finding that PEPD G278D is active in drug-resistant HER2-BC with a clear mechanism, together with the fact that PEPD G278D is a recombinant human protein and does not show adverse effects in mouse studies, provides a strong is mean ± SEM. **P < 0.01, ***P < 0.001, ****P < 0.0001 by one-way ANOVA, followed by Tukey test.
scientific premise for its evaluation in patients with HER2-BC that does not respond to current HER2 inhibitors.
MATERIALS AND METHODS
Study design
This study aimed to determine whether PEPD G278D is active in preclinical models of HER2-BC resistant to clinically available HER2 inhibitors and, if so, its mechanism of action. We first evaluated PEPD G278D in human HER2-BC cell lines that show either primary or acquired resistance to one or more current HER2 inhibitors. PEPD G278D was compared to Ttzm, which is the mainstay treatment for HER2-BC. As positive and negative controls, we included a HER2-BC cell line sensitive to Ttzm and a BC cell line lacking HER2. The cell lines were characterized for key molecular features, including expression of HER2, MUC4, and PTEN, as well as PIK3CA mutation. We measured the effect of each agent on cell proliferation and survival. Each experiment was performed three times. We also measured the modulation of HER2 and other molecules in all the cell lines. The end points were predetermined. To elucidate the mechanism of action of PEPD G278D , we focused on two HER2-BC cell lines, with one showing primary drug resistance (JIMT-1 cells) and the other showing acquired drug resistance (BT-474R2 cells). In addition, CHO-K1 cells with or without expression of human HER2 were used to aid the mechanistic investigation. Once the cell line experiments showed promising activity of PEPD
G278D
, we proceeded to in vivo experiments, comparing the therapeutic effects of PEPD G278D and Ttzm in two orthotopic mouse models of drug-resistant HER2-BC. We established tumors by inoculating JIMT-1 cells or BT-474R2 cells into the mammary fat pads of female mice. The cell lines were selected to represent both primary and acquired drug resistance in HER2-BC. We used two strains of mice: SCID and athymic nude mice. In addition to comparing PEPD G278D with Ttzm, we also evaluated the therapeutic benefit of combining PEPD G278D with paclitaxel, because paclitaxel is commonly used to treat patients with HER2-BC. We did not use statistics to predetermine sample size. Sample size in the mouse experiments was estimated on the basis of our recent studies (18, 19) . Randomization was used in assignment of mice to different treatment groups. Sample size varied slightly among treatment groups in each experiment due to xenograft failure in some mice. Investigators were not blinded during experimental treatment and data collection. All experimental treatments were stopped either because all tumors in a treatment group had disappeared completely or to obtain an adequate amount of tumor tissue from all treatment groups for molecular analysis. No data were excluded.
PEPD
G278D and other materials PEPD G278D was generated in Escherichia coli using pBAD/TOPO-PEPD G278D -His, purified by nickel nitrilotriacetic acid-agarose chromatography, concentrated in phosphate-buffered saline (PBS) using Ultracel YM-30 Centricon (Millipore), and quantified by the bicinchoninic acid (BCA) assay, as previously reported (53) . All other materials were purchased commercially and are described in Supplementary Materials and Methods. -1902) were from the American Type Culture Collection. JIMT-1 (ACC-589) was from the Deutsche Sammlung von Mikroorganismen und Zellkulturen. BT-474R2 was provided by M. Scaltriti of Memorial Sloan Kettering Cancer Center. All cell lines were mycoplasma free and were authenticated using short tandem repeat analysis. Cells were cultured with suitable medium containing 10% fetal bovine serum in humidified incubators with 5% CO 2 at 37°C. Additional information is provided in Supplementary Materials and Methods.
Measurement of cell proliferation and cell viability
Cell proliferation was measured by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay in 96-well plates. Cells were seeded in each well with 150 l of medium and, after overnight growth, treated with vehicle or test agents in 200 l of medium for up to 72 hours and then incubated with medium containing 9.2 mM MTT (200 l per well) for 3 hours at 37°C. The cells were then washed once with PBS and mixed with dimethyl sulfoxide (150 l per well). Cell density in each well was determined by measuring MTT reduction to formazan spectroscopically at 570 nm using a SpectraMax microtiter plate reader (Molecular Devices).
Cell viability was measured by trypan blue exclusion assay. Cells were grown in six-well plates and, after experimental treatments, were trypsinized and suspended in fresh medium. About 550 cells in 10 l of suspension was mixed with 10 l of 0.4% trypan blue solution, and viable cells (unstained cells) were counted using a hemocytometer under an inverted microscope. Additional information is provided in Supplementary Materials and Methods.
Immunoblotting and immunoprecipitation
Protein concentrations in whole-cell lysates, tissue homogenates, and other samples were measured by the BCA assay. For IB, each sample was resolved by SDS-polyacrylamide gel electrophoresis (SDS-PAGE; 8 to 12.5%). Proteins were transferred to polyvinylidene fluoride membrane, probed with specific antibodies, and detected using either Luminata Classico or Luminata Crescendo. Certain IB bands were quantified by ImageJ (National Institutes of Health). For IP, wholecell lysates (0.5 mg protein per sample) were incubated overnight at 4°C with the required antibody in 500 l of volume, followed by incubation with 30 l of Protein G Sepharose beads (2 mg/ml) for 1 hour at room temperature (RT). The beads were washed with IP buffer, suspended in 2× SDS loading buffer, boiled for 5 min, and analyzed by IB. Information about the antibodies is provided in Supplementary Materials and Methods.
Measurement of PEPD
G278D
-induced dimerization of HER2 BT-474R2 and JIMT-1 cells were seeded at 1 × 10 6 cells per well with 0.2 ml of medium in six-well plates and, 24 hours later, treated with vehicle or PEPD G278D (25 nM) for 10 or 60 min. The cells were then washed with ice-cold PBS and incubated with 1 ml per well of 2 mM cross-linker BS3 for 30 min at RT. The cross-linking reaction was terminated by adding 1 ml of 100 mM tris (pH 7.5) to each well, followed by incubation at RT for 15 min. Whole-cell lysates were prepared and analyzed by IB (3.5% SDS-PAGE).
Immunofluorescence staining and confocal microscopy Cells were grown overnight in eight-well chamber slides (1.5 × 10 4 cells per well with 0.3 ml of medium), followed by treatment with chloroquine, PEPD G278D , or vehicle. The cells were then washed with ice-cold PBS, fixed with 4% paraformaldehyde for 15 min at RT, washed again with ice-cold PBS, and blocked with 1% bovine serum albumin in PBS for 45 min at RT. The cells were then incubated with a HER2 antibody and a LAMP1 antibody for 1 hour at RT, washed with PBS, incubated with goat anti-mouse immunoglobulin G (IgG) Alexa Fluor 488 conjugate (for LAMP1 detection) and goat anti-rabbit IgG Alexa Fluor Plus 647 conjugate (for HER2 detection) for 1 hour at RT, and washed again with PBS. The cells were mounted with ProLong Gold Antifade Mountant containing DAPI and then examined using an LSM 510 confocal microscope with a 63× 1.4 PlanApochromat oil immersion objective (Zeiss). To assess PEPD G278D and HER2 colocalization, cells were treated with PEPD G278D for 0 or 15 min or 3 hours. After fixing and blocking as described above, the cells were incubated with a HER2 antibody and a His antibody (for the His tag on PEPD G278D ) for 1 hour at RT, washed with PBS, incubated with goat anti-mouse IgG Alexa Fluor 488 conjugate (for PEPD G278D detection) and goat anti-rabbit IgG Alexa Fluor Plus 647 (for HER2 detection) for 1 hour at RT, and washed again with PBS. The cells were mounted using ProLong Gold Antifade Mountant containing DAPI and then examined using a Zeiss LSM 510 confocal microscope with a 63× 1.4 Plan-Apochromat oil immersion objective. Merged images from z-stack were organized using the ImageJ software. All antibodies are listed in Supplementary Materials and Methods.
Reverse transcription polymerase chain reaction
Total RNA was isolated using the RNeasy mini kit; 500 ng of RNA per sample was reverse-transcribed into complementary DNA (cDNA) in 25 l of reaction using the TaqMan Reverse Transcription Reagents. The reverse transcription reaction was performed at 25°C for 10 min, followed by heating at 48°C for 30 min, and then 95°C for 5 min. Each PCR amplification was carried out in 20 l of volume, containing 10 l of GoTaq Master Mix (2×), 0.5 to 1 l of the reverse-transcribed mixture (cDNA), 0.25 M each of specific forward and reverse primers. The primers were as follows: for human HER2, 5′-CT-GTTTGCCGTGCCACCCTGAGT-3′ (forward) and 5′-CTTCT-GCTGCCGTCGCTTGATGAG-3′ (reverse); for human GAPDH, 5′-CCAGGGCTGCTTTTAACTC-3′ (forward) and 5′-GCTC-CCCCCTGCAAATGA-3′ (reverse). The PCR conditions used for all reactions are as follows: 94°C for 3 min, 28 cycles (HER2) or 25 cycles (GAPDH) at 94°C (denaturation) for 30 s, 63°C (HER2)/60°C (GAPDH) for 30 s (annealing), and 72°C for 30 s (extension); the final extension was performed at 72°C for 5 min. The PCR products were analyzed by electrophoresis with 1% agarose gel, stained by ethidium bromide, and visualized under ultraviolet light. 6 cells in 0.1 ml of 50% Matrigel/50% serum-free DMEM per site). Because BT-474R2 tumor growth is estrogen dependent, a 0.72-mg 17-estradiol pellet for 60-day release was implanted subcutaneously in each mouse 1 day before cell inoculation. Another pellet was implanted in mice after 60 days. Mice in each tumor model were randomized cage-wise into treatment groups using Research Randomizer (www.randomizer.org). Tumor size was measured using length × width 2 ÷ 2. Tumor volume was measured three times each week. Drug treatment was started once tumor size reached 100 to 150 mm 3 . EP (0.5 mg/kg) was administered intraperitoneally to mice once daily. PEPD G278D (4 or 8 mg/kg) was administered intraperitoneally to mice thrice weekly (Monday, Wednesday, and Friday) unless indicated otherwise. Ttzm (10 mg/kg) and paclitaxel (20 mg/kg) were administered intraperitoneally to mice once weekly. EP and PEPD G278D were each prepared and administered to mice in PBS. Ttzm was first prepared in water at 21 mg/ml and diluted with PBS for administration. Paclitaxel was first prepared at 6 mg/ml containing about 50% alcohol and 50% polyoxyl 35 castor oil (v/v), which was diluted with PBS for administration. Each agent was administered to mice at 0.1 ml of volume per 20 g body weight. When a mouse was given multiple agents on the same day, the agents were dosed at about 1-hour intervals. The mice were closely monitored for sign of adverse effects, weighed three times each week, and were euthanized 24 hours after the last treatment, at which point the tumors were promptly removed, snap-frozen, and stored at −80°C for later analysis. One group of mice in the JIMT-1 model showed complete tumor remission after treatment with EP plus PEPD G278D and were maintained for observation without treatment for 60 days. In one experiment using the BT-474R2 model, heart, kidney, and liver were also removed from each mouse when it was euthanized and weighed, and the organs were stored at −80°C for later molecular analysis. Some tumors were fixed in 10% buffered formalin, paraffin-embedded, cut at 4 m, and stained with hematoxylin and eosin for histological analysis.
Statistical analysis
All statistical analyses were carried out using GraphPad Prizm. For two-group comparison, we used paired two-tailed t test. For multigroup comparisons, we used ANOVA followed by Tukey test. P value of 0.05 or lower was considered statistically significant. Additional information is provided in figure legends. Original data are provided in table S1.
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